RankAlpha logo
Back to Rankings

KRRO

Korro BioF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
KRRO-121 trial clearance and dosing, followed by credible human data, could validate Korro's platform; a third candidate and the reported runway provide additional development capacity [#8-K-2026-08-19][#SEC-8K-2026-08-06].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Cash runway is a management projection; sustained R&D spending, financing needs and dilution remain risks [#SEC-8K-2026-08-06].
Momentum
10
Value
41
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.00 · Bull $18.00 · Bear $4.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $20.00
Why
Momentum10 · Δ7d +5.4
Value41 · Δ7d -0.1
Sentiment42 · Δ7d -37.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta -0.1.

Contradictions & invalidation

  • • Cash runway is a management projection; sustained R&D spending, financing needs and dilution remain risks [#SEC-8K-2026-08-06].
  • • First-in-human KRRO-121 regulatory, safety, enrollment and dosing risks [#8-K-2026-08-19].
  • • Trial clearance or enrollment may slip, and preclinical KRRO-111 results may not translate to patients.

Catalyst clock

2026-11-11

Novo Nordisk collaboration hold-period outcome

Lead driver: Value · See fundamentals
Momentum
10
8% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
+1.5
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
42
45% active weight
Current posture
7d trendSoftening
Δ7d
-37.5
Δ21d
-33.2
Why this grade

Composite grade F. Momentum 10.2 / Value 40.6 / Sentiment 42.1

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method

B+
Bull case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$176.41M
Beta
2.98
Shares Out
14.73M
P/E (TTM) · Derived
-1.0
P/S (TTM)
10.22
P/FCF (TTM) · Derived
-1.97
Rev YoY
-100.0%
EPS YoY
-60.9%
Gross Margin
-10.4%
Op Margin
-1366.4%
Net Debt
-$32.67M
Current Ratio
9.55
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data